|
|
 | | | |
- close
- close
- close
- close
| |||||||||
These excerpts taken from the BITI 10-K filed Mar 5, 2008. Musculoskeletal
Therapeutics
Anti-inflammatory clinical trials, such as those focused on
arthritis, include radiologic evaluation of the bones and joints
to determine drug efficacy. We believe that demand among
pharmaceutical companies for our services will increase as new
classes of biotechnology-derived drugs enter and progress
through the clinical development pipeline.
Osteoporosis is a disease characterized by thinning bones, which
leads to fractures in the elderly. The FDA guidance document for
developing treatments for this disease recognized DEXA as one of
the primary efficacy and safety measurement tools available.
Furthermore, all data needs to go through a quality assurance
laboratory. This is now standard practice in all studies using
DEXA instruments whether for osteoporosis, oncology or
anti-obesity, or muscle wasting assessment.
Musculoskeletal Therapeutics Anti-inflammatory clinical trials, such as those focused on arthritis, include radiologic evaluation of the bones and joints to determine drug efficacy. We believe that demand among pharmaceutical companies for our services will increase as new classes of biotechnology-derived drugs enter and progress through the clinical development pipeline. Osteoporosis is a disease characterized by thinning bones, which leads to fractures in the elderly. The FDA guidance document for developing treatments for this disease recognized DEXA as one of the primary efficacy and safety measurement tools available. Furthermore, all data needs to go through a quality assurance laboratory. This is now standard practice in all studies using DEXA instruments whether for osteoporosis, oncology or anti-obesity, or muscle wasting assessment. This excerpt taken from the BITI 10-K filed Mar 29, 2007. Musculoskeletal
Therapeutics
Anti-inflammatory clinical trials, such as those focused on
arthritis, include radiologic evaluation of the bones and joints
to determine drug efficacy. We believe that demand among
pharmaceutical companies for our services will increase as new
classes of biotechnology-derived drugs enter and progress
through the clinical development pipeline.
Osteoporosis is a disease characterized by thinning bones, which
leads to fractures in the elderly. The FDA guidance document for
developing treatments for this disease recognized DEXA as one of
the primary efficacy and safety measurement tools available.
Furthermore, all data needs to go through a quality assurance
laboratory. This is now standard practice in all studies using
DEXA instruments whether for osteoporosis, oncology or
anti-obesity, or muscle wasting assessment.
This excerpt taken from the BITI 10-K filed Mar 16, 2006. Musculoskeletal Therapeutics
Anti-inflammatory clinical trials, such as those focused on arthritis, include radiologic evaluation of the bones and joints to determine drug efficacy. We believe that demand among pharmaceutical companies for our services will increase as new classes of biotechnology-derived drugs enter and progress through the clinical development pipeline.
Osteoporosis is a disease characterized by thinning bones, which leads to fractures in the elderly. The FDA guidance document for developing treatments for this disease recognized DEXA as one of the primary efficacy and safety measurement tools available. Furthermore, all data needs to go through a quality assurance laboratory. This is now standard practice in all studies using DEXA instruments whether for osteoporosis, oncology or anti-obesity, or muscle wasting assessment.
| EXCERPTS ON THIS PAGE:
|
| |||||||
